The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice
Open Access
- 1 March 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 164 (5) , 2354-2361
- https://doi.org/10.4049/jimmunol.164.5.2354
Abstract
Several HLA-A*0201-restricted peptide epitopes that can be used as targets for active immunotherapy have been identified within melanocyte differentiation proteins. However, uncertainty exists as to the most effective way to elicit CD8+ T cells with these epitopes in vivo. We report the use of transgenic mice expressing a derivative of HLA-A*0201, and dendritic cells, to enhance the activation of CD8+ T cells that recognize peptide epitopes derived from human tyrosinase and glycoprotein 100. We find that by altering the cell surface density of the immunizing peptide on the dendritic cells, either by pulsing with higher concentrations of peptide, or by changing the MHC-peptide-binding affinity by generating variants of the parent peptides, the size of the activated CD8+ T cell populations can be modulated in vivo. Significantly, the density of peptide that produced the largest response was less than the maximum density achievable through short-term peptide pulsing. We have also found, however, that while some variant peptides are effective at eliciting both primary and recall CD8+ T cell responses that can recognize the parental epitope, other variant epitopes lead to the outgrowth of CD8+ T cells that only recognize the variant. HLA-A*0201 transgenic mice provide an important model to define which peptide variants are most likely to stimulate CD8+ T cell populations that recognize the parental, melanoma-specific peptide.Keywords
This publication has 51 references indexed in Scilit:
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Supraoptimal Peptide–Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor α Receptor II–mediated Apoptosis of Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1998
- HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout MiceThe Journal of Experimental Medicine, 1997
- Human tumor antigens recognized by T lymphocytes.The Journal of Experimental Medicine, 1996
- THE IMMUNOTHERAPY OF SOLID CANCERS BASED ON CLONING THE GENES ENCODING TUMOR-REJECTION ANTIGENSAnnual Review of Medicine, 1996
- An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.The Journal of Experimental Medicine, 1996
- Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic miceInternational Immunology, 1995
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex.The Journal of Experimental Medicine, 1991